Oncology

A recent Phase I clinical trial has provided promising results for a novel immunotherapy approach to treat early-stage ERBB2-positive breast cancer.

A recent study suggests multi-ancestry polygenic risk scores (PRS) may help refine active surveillance strategies for low- to intermediate-risk prostate cancer.

Selpercatinib, a targeted RET kinase inhibitor, has demonstrated continued efficacy in treating RET fusion-positive non–small cell lung cancer (NSCLC) even after disease progression.

A recent Phase II clinical trial has revealed promising results for men with low-grade prostate cancer on active surveillance (AS).

A new AI-powered model predicts outcomes for breast cancer patients on CDK4/6 inhibitors, offering precise insights into treatment response and enabling personalized care.

In this study, patients with a recurrence scores greater than 31 exhibited significant improvements in survival outcomes when treated with taxane and anthracycline-based chemotherapy.

Findings, presented at SABCS 2024, support tamoxifen as an effective adjuvant therapy for reducing recurrence in women with “good-risk” DCIS who opt to skip RT.

Avoiding chest wall irradiation post-mastectomy is safe for most intermediate-risk breast cancer patients, improving quality of care.

A novel deep learning-based radiomic biomarker could significantly enhance prediction of response to immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC).

Patients with low-risk ductal carcinoma in situ (DCIS) who chose active monitoring over immediate surgery reported similar quality-of-life outcomes, according to findings from the COMET trial presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

Risk-reducing surgeries, including bilateral mastectomy (RRM) and salpingo-oophorectomy (RRSO), are associated with improved survival outcomes in BRCA-mutation carriers diagnosed with breast cancer at or before age 40, according to a study presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

Active monitoring may be a safe and effective treatment option for patients with low-risk ductal carcinoma in situ (DCIS), according to the findings of the COMET trial presented at the San Antonio Breast Cancer Symposium (SABCS) 2024.

At the 2024 San Antonio Breast Cancer Symposium (SABCS), new Phase III trial data presented the promising results of imlunestrant, an oral next-generation selective estrogen receptor degrader (SERD), in patients with advanced breast cancer.

Daily glucocorticoid hormones, commonly prescribed to reduce inflammation, can significantly influence the progression of glioblastoma (GBM), the most aggressive brain cancer in adults, according to new research.

Patients with high-risk, BRCA-positive breast cancer receiving the PARP inhibitor olaparib after standard treatment continue to experience significant survival benefits, according to 6-year follow-up results from the Phase III OlympiA trial.

Socioeconomic barriers and medical distrust hindered COVID-19 vaccine completion among cancer survivors, a high-risk group for severe outcomes from the virus, according to a recent study.

Over the past 45 years, cancer prevention and screening interventions have averted nearly 6 million deaths from major cancers in the United States, according to new research.

Emerging data highlights a critical complication for patients with metastatic lung cancer undergoing treatment with immune checkpoint inhibitors (ICIs), including PD-1 and PD-L1 blockers.

Patients with cancer vaccinated against COVID-19 within 6 months before infection showed significantly higher survival rates, according to a new analysis from the ASCO COVID-19 Registry.

Agricultural pest management methods were explored in a new study to determine how they can be adapted to combat cancer treatment resistance.

Glucose restriction in the tumor microenvironment helps cancer cells survive chemotherapy by altering key metabolic pathways, reveals a new study.

A recent analysis of the IDEAL clinical trial highlights a breakthrough for early-stage breast cancer.

Patients with multiple sclerosis (MS) may experience a slightly increased risk of developing cancer compared to the general population, according to a new nationwide French study spanning 10 years.

Mailed fecal immunochemical testing (FIT) kits using centralized outreach significantly increases colorectal cancer (CRC) screening rates in underserved communities, according to the results of a new study.